Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

The clinical use of PET with (11)C-acetate.

Grassi I, Nanni C, Allegri V, Morigi JJ, Montini GC, Castellucci P, Fanti S.

Am J Nucl Med Mol Imaging. 2012;2(1):33-47. Epub 2011 Dec 15.

2.

Positron emission tomography for prostate, bladder, and renal cancer.

Schöder H, Larson SM.

Semin Nucl Med. 2004 Oct;34(4):274-92. Review.

PMID:
15493005
3.

A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.

Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH.

J Nucl Med. 2008 Dec;49(12):1912-21. doi: 10.2967/jnumed.108.055087. Epub 2008 Nov 7.

4.

Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?

Cheung TT, Chan SC, Ho CL, Chok KS, Chan AC, Sharr WW, Ng KK, Poon RT, Lo CM, Fan ST.

Liver Transpl. 2011 Oct;17(10):1218-25. doi: 10.1002/lt.22362.

5.

Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma.

Ho CL, Chen S, Ho KM, Chan WK, Leung YL, Cheng KC, Wong KN, Cheung MK, Wong KK.

Clin Nucl Med. 2012 Nov;37(11):1075-82. doi: 10.1097/RLU.0b013e318266cde2.

PMID:
22996247
6.

Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.

Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR.

Eur J Nucl Med Mol Imaging. 2003 Apr;30(4):607-11. Epub 2003 Feb 13.

PMID:
12589476
7.

The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review.

Treglia G, Giovannini E, Di Franco D, Calcagni ML, Rufini V, Picchio M, Giordano A.

Ann Nucl Med. 2012 Jul;26(6):451-61. doi: 10.1007/s12149-012-0602-7. Epub 2012 May 8. Review.

PMID:
22566040
8.

The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma.

Yun M, Bang SH, Kim JW, Park JY, Kim KS, Lee JD.

J Nucl Med. 2009 Aug;50(8):1222-8. doi: 10.2967/jnumed.109.062703. Epub 2009 Jul 17.

9.

11C-acetate PET imaging of prostate cancer.

Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K.

J Nucl Med. 2002 Feb;43(2):181-6.

10.

Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.

Ho CL, Chen S, Yeung DW, Cheng TK.

J Nucl Med. 2007 Jun;48(6):902-9. Epub 2007 May 15.

11.

Assessment of tissue viability with fluorine-18-fluoro-2-deoxyglucose (FDG) and carbon-11-acetate PET imaging.

Schröter G, Schneider-Eicke J, Schwaiger M.

Herz. 1994 Feb;19(1):42-50. Review.

PMID:
8150413
12.

11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.

Ho CL, Yu SC, Yeung DW.

J Nucl Med. 2003 Feb;44(2):213-21.

13.

Imaging a pancreatic carcinoma xenograft model with 11C-acetate: a comparison study with 18F-FDG.

Zhao C, Chen Z, Ye X, Zhang Y, Zhan H, Aburano T, Tian M, Zhang H.

Nucl Med Commun. 2009 Dec;30(12):971-7. doi: 10.1097/MNM.0b013e328330adfc.

PMID:
19696689
14.

F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma.

Wu HB, Wang QS, Li BY, Li HS, Zhou WL, Wang QY.

Clin Nucl Med. 2011 Dec;36(12):1092-7. doi: 10.1097/RLU.0b013e3182335df4.

PMID:
22064078
15.

Evaluation of patients with hepatocellular carcinomas using [(11)C]acetate and [(18)F]FDG PET/CT: A preliminary study.

Hwang KH, Choi DJ, Lee SY, Lee MK, Choe W.

Appl Radiat Isot. 2009 Jul-Aug;67(7-8):1195-8. doi: 10.1016/j.apradiso.2009.02.011. Epub 2009 Feb 20.

PMID:
19342249
16.

Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.

Dimitrakopoulou-Strauss A, Strauss L.

Hell J Nucl Med. 2006 Jan-Apr;9(1):10-21.

PMID:
16617388
17.

[Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].

Machtens S, Boerner AR, Hofmann M, Knapp WH, Jonas U.

Urologe A. 2004 Nov;43(11):1397-409. Review. German.

PMID:
15502907
18.

Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases.

Chua S, Gnanasegaran G, Cook GJ.

Semin Nucl Med. 2009 Nov;39(6):416-30. doi: 10.1053/j.semnuclmed.2009.07.002. Review.

PMID:
19801221
19.

11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET.

Higashi K, Ueda Y, Matsunari I, Kodama Y, Ikeda R, Miura K, Taki S, Higuchi T, Tonami H, Yamamoto I.

Eur J Nucl Med Mol Imaging. 2004 Jan;31(1):13-21. Epub 2003 Oct 22.

PMID:
14574513
20.

11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness.

Shibata H, Nomori H, Uno K, Iyama K, Tomiyoshi K, Nakashima R, Sakaguchi K, Goya T, Takanami I, Koizumi K, Suzuki T, Kaji M, Horio H.

Ann Nucl Med. 2009 Sep;23(7):609-16. doi: 10.1007/s12149-009-0278-9. Epub 2009 Jun 30.

PMID:
19562438
Items per page

Supplemental Content

Write to the Help Desk